Cargando…

Overcoming AC220 resistance of FLT3-ITD by SAR302503

Detalles Bibliográficos
Autores principales:	Kesarwani, M, Huber, E, Azam, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763391/ https://www.ncbi.nlm.nih.gov/pubmed/23995047 http://dx.doi.org/10.1038/bcj.2013.40

Ejemplares similares

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
por: Wang, Peihong, et al.
Publicado: (2021)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
por: Yang, Jing, et al.
Publicado: (2021)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias
por: Lipka, D B, et al.
Publicado: (2016)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
por: Xiao, Xinhua, et al.
Publicado: (2023)

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
por: Zorn, Julie A., et al.
Publicado: (2015)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others
por: de Arruda, Vanessa Y.N., et al.
Publicado: (2017)

A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice
por: Mupo, A, et al.
Publicado: (2013)

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model
por: Carter, Bing Z., et al.
Publicado: (2023)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia
por: Matsukawa, Toshihiro, et al.
Publicado: (2023)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
por: Minetto, Paola, et al.
Publicado: (2020)

The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Su, Long
Publicado: (2019)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality
por: Zalpoor, Hamidreza, et al.
Publicado: (2022)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia FLT3-ITD patients
por: Vignal, Nicolas, et al.
Publicado: (2023)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21(Cdkn1a) and Pbx1 in Hematopoietic Cells
por: Abe, Mariko, et al.
Publicado: (2016)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
por: Sportoletti, Paolo, et al.
Publicado: (2019)

Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations
por: Porter, Shaina N, et al.
Publicado: (2016)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
por: Qiu, Yang, et al.
Publicado: (2023)

RUNX1 cooperates with FLT3-ITD to induce leukemia
por: Behrens, Kira, et al.
Publicado: (2017)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
por: Shimony, Shai, et al.
Publicado: (2023)

Wild‐type FLT3 and FLT3 ITD exhibit similar ligand‐induced internalization characteristics
por: Kellner, Fabienne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9v3gk4g2vt5tfuemc60hgm8us8